<DOC>
	<DOCNO>NCT01960374</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability PK selumetinib ( AZD6244 ; ARRY-142886 ) ( Hyd-Sulfate ) healthy male Japanese non-Japanese Asian volunteer follow administration single dose . Standard safety assessment include ECGs , vital sign , blood/urine safety test , PK sample monitor adverse event optional exploratory pharmacogenetics perform .</brief_summary>
	<brief_title>Dose-escalation Study Assess Selumetinib Safety , Tolerability PK</brief_title>
	<detailed_description>A Phase I , Single-centre , Open-label , Dose-escalation Study Assess Safety , Tolerability Pharmacokinetics Selumetinib ( AZD6244 ; ARRY-142886 ) ( Hyd-Sulfate ) Given Orally Japanese Non-Japanese Asian Healthy Male Volunteers</detailed_description>
	<criteria>Provision sign date , write informed consent prior studyspecific procedure . Nonsmokers least three month prior drug administration . Healthy male volunteer age 18 55 year suitable vein cannulation repeat venipuncture . Subjects include either healthy first generation Japanese , healthy first generation nonJapanese Asian ( e.g . Korean , Chinese ) . Japanese subject must meet following requirement order participate study : Subject born Japan , Parents grandparent ( maternal paternal ) Japanese Subject possession valid Japanese passport , Expatriate Japan longer 5 year . NonJapanese Asian subject must meet following requirement order participate study : Subject born Asian country Japan , ( Korea , China , Taiwan etc India ) , Parents grandparent ( maternal paternal ) nonJapanese Asian Subject possession valid passport country origin , Expatriate country origin longer 5 year ; Have BMI 18 30 kg/m2 inclusive weigh least 50 kg 100 kg , inclusive . Must use acceptable method contraception male subject 's partner could become pregnant time first administration treatment study medication 3 month follow administration last treatment dose study medication . History clinically important disease disorder , opinion investigator , may either put volunteer risk participation study , influence result volunteer 's ability participate study History presence gastrointestinal , hepatic , renal disease condition know interfere absorption , distribution , metabolism , excretion drug . Any clinically important illness , medical/surgical procedure , trauma within 4 week first administration IMP . Any clinically significant abnormality clinical chemistry , haematology , urinalysis result , judged Investigator . Any positive result screen serum hepatitis B surface antigen ( HbsAg ) , anti hepatitis core antibody ( anti HBc Ig G [ anti HBc IgM IgG positive ] , hepatitis C antibody ( anti HCV ) , HIV 1 2 antibody ( anti HIV 1/2 ) . Abnormal vital sign , 10 minute supine rest . Current past history central serous retinopathy retinal vein thrombosis , intraocular pressure great 21 mmHg uncontrolled glaucoma . Known suspected history drug abuse , judge Investigator . History alcohol abuse excessive intake alcohol , judge Investigator . Positive screen drug abuse cotinine ( nicotine ) positive screen alcohol screen admission study centre Day 1 . History severe allergy/hypersensitivity ongoing clinically important allergy/hypersensitivity , judge Investigator , history hypersensitivity drug similar chemical structure class selumetinib . Excessive intake caffeinecontaining drink food eg , coffee , tea , chocolate , Red Bull , cola ( 6 unit caffeine per day ) . Use drug enzymeinducing property St John 's Wort within 3 week prior first administration IP . Use prescribe non prescribed medication include antacid , analgesic paracetamol/acetaminophen 1 g 4 time day occasional use , herbal remedy , vitamin , mineral 2 week five halflives compound , whichever longer , prior first administration IP . Any intake grapefruit , grapefruit juice , Seville oranges , Seville orange marmalade , product contain grapefruit Seville oranges within 7 day first admission Day 1.Plasma donation within 1 month screen blood donation/blood loss great 500 mL 3 month prior screen . Has receive another new chemical entity ( define compound approve marketing ) participate clinical study include drug treatment within least 3 month first administration IP study . The period exclusion begin 3 month final dose 1 month last visit whichever long . Note : volunteer consent screen , randomize study previous Phase I study , excluded.Previous administration study IP present study . involvement plan and/or conduct study RPL/third party contractor AstraZeneca employee close relative regardless role accordance internal procedure . judge Investigator volunteer participate study ongoing recent ( i.e. , screen period ) minor medical complaint may interfere interpretation study data consider unlikely comply study procedure , restriction , requirement . Volunteers previously receive selumetinib . Volunteers vegans medical dietary restriction . Volunteers communicate reliably Investigator . In addition , follow regard criterion exclusion genetic research : Previous bone marrow transplant , nonleukocyte deplete whole blood transfusion within 120 day date genetic sample collection</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>RAS RAF oncogene , Inhibition MEK pathway , inhibition cancer cell proliferation promise anti-cancer therapeutic strategy .</keyword>
</DOC>